Abstract:Introduction: The effects of the SARS-CoV-2 virus on the body, and why the effects are more severe in certain patients, remain incompletely understood. One population of special interest is transplant recipients because of their immunosuppressed state. Understanding the pathophysiology of graft dysfunction in transplant patients with the COVID-19 viral syndrome is important for prognosticating the risk to the graft as well as understanding how best to prevent and, if necessary, treat graft injury in these patients. Methods: We analyzed multiple types of solid organ transplant recipients (liver, kidney, heart or lung) at our institution who died from SARS-CoV-2 and underwent autopsy (n = 6) or whose grafts were biopsied during active SARS-CoV-2 infection (n = 8). Their serum inflammatory markers were examined together with the histological appearance, viral load, and TCR repertoire of their graft tissue and, for autopsy patients, several native tissues. Results: Histology and clinical lab results revealed a systemic inflammatory pattern that included elevated inflammatory markers and diffuse tissue damage regardless of graft rejection. Virus was detected throughout all tissues, although most abundant in lungs. The TCR repertoire was broadly similar throughout the tissues of each individual, with greater sharing of dominant clones associated with more rapid disease course. There was no difference in viral load or clonal distribution of overall, COVID-associated, or putative SARS-CoV-2-specific TCRs between allograft and native tissue. We further demonstrated that SARSCoV-2-specific TCR sequences in transplant patients lack a donor HLArestricted pattern, regardless of distribution in allograft or native tissues,suggesting that recognition of viral antigens on infiltrating recipient cells can effectively trigger host T cell anti-viral responses in both the host and graft. Discussion: Our findings suggest a systemic immune response to the SARS-CoV-2 virus in solid organ transplant patients that is not associated with rejection and consistent with a largely destructive effect of recipient HLA-restricted T cell clones that affects donor and native organs similarly.

Solid organ transplantation in SARS-CoV-2 positive recipients: a web-survey among ESGICH members

Current management of SARS‐CoV‐2 infection in solid organ transplant recipients: Experience derived from an ESGICH–ESOT survey

SARS-CoV-2 Infection in Transplant-Related Biology: Where Do We Stand?

Solid Organ Transplantation in SARS-CoV-2 Recovered Transplant Candidates: a Comprehensive Review of Recent Literature

Coronavirus Disease 2019 in Solid Organ Transplant: A Multicenter Cohort Study

Solid organ transplantation programs facing lack of empiric evidence in the COVID-19 pandemic: A By-proxy Society Recommendation Consensus approach

Monocentric, Retrospective Study on Infectious Complications within One Year after Solid-Organ Transplantation at a Belgian University Hospital

P478 HEART TRANSPLANT IN SARS–COV2 POSITIVE RECIPIENT: MANAGEMENT PROTOCOL OF WORLD‘S FIRST CASE

Challenges Faced by Solid Organ Transplant Recipients During the COVID-19 Pandemic in France: Historical Insights and Key Takeaways

Early impact of COVID‐19 on transplant center practices and policies in the United States

COVID-19 in Solid Organ Transplant Recipients in Spain Throughout 2020: Catching the Wave?

COVID‐19 in organ donors: An organ procurement organization perspective

COVID-19 Outcomes and Vaccinations in Swedish Solid Organ Transplant Recipients 2020–2021: A Nationwide Multi-Register Comparative Cohort Study

Characterization of the Antibody Response to SARS-CoV-2 Infection in COVID-19 Transplant versus Nontransplant Recipients by Ig-MS

Recipient donor sex combinations in solid organ transplantation and impact on clinical outcome: A scoping review

T cell repertoire profiling in allografts and native tissues in recipients with COVID-19 after solid organ transplantation: Insight into T cell-mediated allograft protection from viral infection

Prospective Clinical, Virologic, and Immunologic Assessment of COVID-19 in Transplant Recipients

Impact of solid organ transplant status on outcomes of hospitalized patients with COVID‐19 infection

Early Impact of COVID-19 on Solid Organ Transplantation in the United States

Evolving Impact of COVID‐19 on Transplant Center Practices and Policies in the United States

Efficacy and Safety of Remdesivir in Adult Solid Organ Transplant Recipients: A Scoping Review